Hypermarcas (OTCMKTS:HYPMY) Releases Earnings Results, Beats Expectations By $0.01 EPS

Hypermarcas (OTCMKTS:HYPMY) announced its earnings results on Wednesday. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01, Zacks reports. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. The business had revenue of $473.13 million during the quarter, compared to the consensus estimate of $450.75 million.

Hypermarcas Stock Down 3.0%

OTCMKTS HYPMY traded down $0.12 during trading on Thursday, reaching $3.96. 63,930 shares of the company’s stock were exchanged, compared to its average volume of 46,671. The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. Hypermarcas has a fifty-two week low of $3.39 and a fifty-two week high of $5.77. The company’s fifty day simple moving average is $4.63 and its 200-day simple moving average is $4.41. The firm has a market capitalization of $2.79 billion, a PE ratio of 7.91 and a beta of 0.78.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.

About Hypermarcas

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.